Research shows that exposing the brain to precisely timed flickers of light and pulses of sound at 40 cycles per second can slow cognitive decline in Alzheimer’s patients.
In clinical trials, this non-invasive approach reduced brain volume loss by up to 69% and preserved daily function over six months compared to placebo treatments.
The technique works without pharmaceuticals, operating through an entirely different mechanism than current medications.
The method, called GENUS—Gamma ENtrainment Using Sensory stimuli—induces the brain to oscillate at 40 hertz, a frequency in the gamma range associated with memory and cognitive processing.
Scientists have tracked its effects through brain imaging and electroencephalography. During treatment sessions, gamma wave strength increases across multiple brain regions, and synchronization between the frontal and occipital lobes improves measurably.
This isn’t theoretical science anymore. The FDA granted breakthrough device designation to Cognito Therapeutics’ gamma frequency neuromodulation system in 2021, recognizing the strength of clinical evidence supporting this approach.
By July 2025, the company’s OVERTURE trial demonstrated that treated participants experienced up to 9.9 months of “time saved” across clinical and imaging endpoints over an 18-month period.
What Traditional Wisdom Gets Wrong
For decades, pharmaceutical companies chased a single target in Alzheimer’s treatment: amyloid plaques. The logic seemed airtight—these protein clumps accumulate in Alzheimer’s brains, so removing them should halt disease progression.
Recently approved drugs like aducanumab and lecanemab clear amyloid plaques and slow cognitive decline by 27-35% after 18 months of treatment. Yet this improvement comes with significant risks and limitations.
Here’s where conventional thinking falters. The pathophysiology of brain wave alterations represents a common denominator for different neuropsychiatric disorders, not being specific for Alzheimer’s alone.
What if the disease isn’t primarily about protein accumulation but about disrupted neural communication?
Researchers previously noted that those with Alzheimer’s have weaker and less synchronized gamma waves than those without the condition. The focus shifted from attacking symptoms to restoring function.
Rather than trying to clear debris from a malfunctioning system, sensory stimulation aims to tune the system back to its proper frequency.
The stimulation appears to alter microglia behavior, preserve neurons and synapses, and improve blood flow in the brain—producing a coordinated response that addresses multiple aspects of the disease simultaneously.
This comprehensive approach distinguishes it from single-target pharmaceuticals.
The Mechanism Behind the Treatment
The human brain houses roughly 86 billion neurons communicating through electrical pulses. When many neurons activate, these pulses synchronize and repeat in organized patterns, creating rhythms called brain waves.
The brain generates five types, classified by frequency—how many cycles complete per second.
Gamma waves operate at the highest frequency, between 32 and 100 Hertz. These specific neuronal activities promote gene and protein expression necessary for preserving cognition and function. In Alzheimer’s patients, this rhythm becomes irregular.
The treatment employs a surprisingly elegant solution. y
By exposing the visual cortex to flickering lights and delivering clicking sounds to the auditory system at exactly 40 Hz, researchers found they could boost gamma wave strength and synchronization in mouse models of Alzheimer’s.
The animals demonstrated memory improvements, delayed neuronal degeneration, and decreased levels of disease-associated proteins compared to controls.
Researchers believe stronger, synchronized gamma waves strengthen neural connections, enlarge waste-clearing arteries, and improve immune cell responsiveness in the brain. The mechanism operates through multiple pathways simultaneously.
The Science Translates to Humans
MIT researchers completed two short clinical trials examining how 40-Hz light and sound treatment affects people. The initial Phase 1 trial involved 43 participants, including 16 people with early-stage Alzheimer’s.
Using scalp electrodes, the team tracked activity in participants’ frontal and occipital lobes before, during, and after sensory stimulation.
Results confirmed the approach translates across species. Gamma wave strength appeared to rise throughout therapy in all brain areas, with gamma wave synchronization increasing between frontal and occipital lobes.
Sleepiness emerged as the most commonly reported side effect, with no serious adverse events recorded.
The Phase 2a trial advanced the research further. Fifteen individuals with early-stage Alzheimer’s received GENUS devices for home use, applying the treatment for one hour daily over at least three months.
This design reflected practical implementation—patients could integrate therapy into their daily routines without clinical supervision.
Structural Brain Changes Emerge
Brain imaging revealed compelling structural preservation. Two metrics linked to Alzheimer’s progression—reduced hippocampal volume and raised ventricle volume—worsened in control participants but did not alter significantly in the treatment group.
The hippocampus plays a critical role in memory formation, making its preservation particularly meaningful.
Results from daily one-hour treatments over six months showed a 69% reduction in brain volume loss, including reduced atrophy in the corpus callosum, a brain region critical for communication between the two hemispheres.
This structural preservation correlated with functional outcomes.
Early clinical trials showed that three months of daily treatment reduced brain atrophy—including in the hippocampus—and strengthened functional connectivity as measured by synchronization across brain regions.
Patients displayed promising cognitive improvements alongside these structural benefits.
The Role of the Glymphatic System
Recent discoveries illuminated another crucial mechanism. A study published in Nature in 2024 introduced an innovative non-invasive approach using visual and auditory stimulation at specific frequencies to modulate neuron activity, inducing the brain lymphatic function for clearance of Amyloid-β from the neurons’ microenvironment.
The brain’s waste clearance system operates differently than previously understood. A team in China independently corroborated in 2024 that 40-hertz sensory stimulation increases glymphatic fluid flows in mice, strengthening the evidence for this mechanism.
This lymphatic drainage removes toxic proteins that accumulate in Alzheimer’s disease.
Arterial vessel imaging in mice revealed that animals receiving stimulation exhibited an increase in arterial pulsation and an increase in the diameter of lymphatic vessels in the meninges compared to the control group.
The enhanced clearance operates through vascular changes driven by neural activity.
Beyond Alzheimer’s: Broader Applications
The comprehensive nature of gamma stimulation’s effects suggests it might benefit other neurological conditions, with studies showing potential applications for Parkinson’s disease, stroke recovery, epilepsy, anxiety, and even the cognitive side effects of chemotherapy.
Researchers demonstrated that audiovisual gamma stimulation protected mice from chemotherapy-induced impairments such as decreased brain volume, DNA damage, inflammation, and cognitive deficits.
The neuroprotective effects extend beyond neurodegenerative disease.
This versatility stems from the fundamental role gamma waves play in neural function. Rather than targeting disease-specific pathology, the approach restores healthy brain rhythms that support multiple protective mechanisms.
Electric Stimulation Enters the Arena
While light and sound capture most attention, electrical brain stimulation also shows promise. In a randomized clinical trial, 60 patients with Alzheimer’s receiving standard care were allocated to treatment groups, with two weeks of transcranial pulse stimulation significantly improving cognitive scores in a younger subsample of patients.
Transcranial pulse stimulation upregulated memory-associated brain activation and functional connectivity in the attention network. The ultrasound-based approach was well tolerated and enhanced cognition through different mechanisms than sensory stimulation.
Repeated sessions of electrical stimulation to brain networks associated with memory improved verbal learning in some Alzheimer’s patients for up to eight weeks in a preliminary trial.
The technique, called transcranial direct current stimulation, sends electrical current through scalp electrodes to alter targeted brain regions.
Transcranial electrical stimulation now allows targeting of deep brain structures involved in cognitive processing, such as the hippocampus or the striatum. This capability expands treatment possibilities beyond surface-level intervention.
Clinical Trial Progress Accelerates
Cognito Therapeutics, a company spun off from MIT research, has initiated a phase 3 trial randomly assigning 500 persons with Alzheimer’s to receive daily 40-Hz auditory and visual stimulation or placebo treatment for 9 to 12 months.
The HOPE trial represents the largest test of this approach to date.
Data from OVERTURE showed that the treatment device resulted in significant “time saved” in functional and structural decline over 6 months and significant “time saved” in cognitive, functional and structural decline over 18 months.
This metric translates abstract measurements into meaningful patient outcomes.
More than 80% of patients adhered to the active treatment regardless of starting during the double-blind or open-label extension period. High adherence rates suggest patients find the therapy tolerable and acceptable for long-term use.
Through treatment, patients showed clinical stability of function at 18 months based on total Activities of Daily Living scores. Maintaining independence in daily activities matters profoundly to patients and caregivers.
Safety Profile Stands Out
Over 40,000 treatment sessions were completed across multiple clinical studies with no serious treatment-limiting adverse events reported. This safety record contrasts sharply with pharmaceutical interventions.
Higher rates of headache (21.7% vs 10.7%) and tinnitus (15.2% vs 0.0%) were found during the randomized trial portion, and safety outcomes remained similar through the 18-month period. These mild side effects rarely prompted treatment discontinuation.
The absence of systemic side effects makes sense given the mechanism. Unlike medications that circulate throughout the body, light and sound therapy works by using pulses set to a particular frequency to interact with brain cells.
The intervention remains localized to neural tissue.
Implementation Challenges and Solutions
Stroboscopic lighting has been shown to cause headaches, dizziness and even epileptic seizures, creating concerns about certain light therapy approaches. Early implementations raised legitimate safety questions.
Technology advanced to address these limitations. Invisible Spectral Flicker technology devised by OptoCeutics uses light flickers that you can’t notice with the naked eye, reducing the probability of adverse symptoms.
This innovation maintains therapeutic effects while eliminating visible flashing.
Light and sound intensity are tailored to each patient based on their tolerability and response to stimulation observed through EEG evaluation. Personalization optimizes outcomes while minimizing discomfort.
During the screening phase, stimulation intensities were tailored for each study participant in the clinical setting and the presence of treatment-evoked 40 Hz steady-state EEG oscillations were verified for study inclusion.
This verification ensures the therapy engages its intended target.
The Home Treatment Advantage
Patients receive treatment in the form of a wearable device for one hour each day, wherever and whenever it is most convenient. This accessibility removes barriers that plague traditional medical interventions.
The treatment device delivers non-invasive visual and auditory stimulation designed to preserve brain structure and function from the comfort of home. No hospital visits, no infusions, no complex medication schedules.
Data presented at AAIC 2025 showed that the device had more than 85% of participants adhering to daily sessions. When treatments fit seamlessly into daily life, compliance improves dramatically.
Combination Therapy Potential
The potential disease-modifying therapy will be instrumental to help mitigate the accelerated brain atrophy caused by anti-amyloid monoclonal antibodies, with no amyloid-related imaging abnormalities shown over 18 months in the Phase 2 extension data. This compatibility opens combination treatment possibilities.
The therapy may act as a combination approach to create a continuum of care for Alzheimer’s disease. Rather than replacing existing treatments, sensory stimulation could complement them.
The multi-pathway mechanism supports this strategy. Combined clinical and biomarker findings suggest beneficial effects of gamma frequency neuromodulation may be facilitated via differentiated pathways compared to traditional pharmacologic approaches.
Different mechanisms working together could produce synergistic effects.
Economic and Access Considerations
If this more extensive experiment can demonstrate the treatment’s success, it could one day provide individuals with Alzheimer’s with a safer strategy to tackle the illness that does not put them in danger of grave side effects. The public health implications extend beyond individual patients.
Traditional Alzheimer’s medications require ongoing medical supervision, regular laboratory monitoring, and management of side effects.
The treatment approach offers an at-home therapeutic that has slowed cognitive and functional decline and loss of brain structure among treated patients in prior clinical studies. Reduced medical oversight requirements could lower costs substantially.
Device-based therapy involves upfront costs but eliminates recurring pharmaceutical expenses.
For its first year, a National Institutes of Health grant provided $792,000 to Mount Sinai researchers testing light therapy combinations. Research funding accelerates development toward widespread availability.
What Researchers Are Learning
Single-nucleus RNA sequencing explored the molecular mechanism of cerebrospinal fluid influx following gamma stimulation, with findings pointing to the Kcnk1 gene that encodes a highly regulated potassium channel localized to astrocytic endfeet.
These cellular structures play critical roles in brain fluid transport.
Studies showed effects extending beyond initially targeted brain regions, with benefits spreading throughout neural networks. The widespread impact suggests systemic improvements in brain function rather than isolated effects.
Cognito highlighted its collaboration with Firefly Neuroscience, analyzing EEG data using Brain Network Analytics platform to identify neurophysiological biomarkers that predict individual patient response and monitor longitudinal changes in brain network activity. Precision medicine approaches could optimize treatment selection.
The Road Ahead
Mount Sinai researchers are testing whether combining 40-Hz flashes with a light therapy designed to reset a patient’s sleep-wake cycle may provide additional benefits. Optimizing treatment protocols continues as research expands.
The field is rapidly evolving with novel techniques and protocols that offer the possibility to develop tailored interventions for Alzheimer’s disease. Multiple institutions worldwide are pursuing parallel research lines.
The larger HOPE study might be completed by May 2025, potentially providing definitive evidence of treatment efficacy. This timeline brings practical implementation within reach.
Patient and Caregiver Perspectives
Unlike other clinical trials in Alzheimer’s disease, patients were not required to have specific threshold values of amyloid as determined by imaging or cerebrospinal fluid testing, allowing more patients to have access to the trial. Broader eligibility increases the potential patient population.
Measurement of daily function and cognition are highly relevant outcomes to patients and their caregivers and are related to measures of disease progression, including brain atrophy.
The treatment targets outcomes that matter most to those living with the disease.
Maintaining independence and quality of life supersedes laboratory markers in importance.
Findings presented at the Alzheimer’s Association International Conference reinforced the potential to not only slow cognitive and functional decline but to provide meaningful structural preservation that could shift the treatment paradigm.
The Science Remains in Motion
A decade of studies from labs around the world provide a growing evidence base that increasing the power of the brain’s gamma rhythms could help fight Alzheimer’s, and perhaps other, neurological diseases. International collaboration strengthens the research foundation.
While these trials imply that 40-Hz GENUS is safe and beneficial for Alzheimer’s patients, the sample sizes are far too limited to prove that sensory stimulation works definitively. Larger trials will determine whether early promise translates to reliable clinical benefit.
The approach represents a fundamental shift in thinking about neurodegenerative disease. Rather than attacking pathological hallmarks with pharmaceuticals, sensory stimulation restores healthy brain rhythms that activate multiple protective mechanisms.
The brain becomes an active participant in its own healing.
This isn’t about replacing medications entirely but expanding the therapeutic toolkit. If successful, the treatment could provide a safer, more accessible alternative that doesn’t carry the risk of serious side effects associated with current drugs.
For millions facing this diagnosis, that possibility offers genuine hope.
References
Sound and Light as Potential Alzheimer’s Treatment
Light And Sound Therapy Treatment For Alzheimer’s Disease – OptoCeutics
Sound and Light Therapy Shows Promising Results in Alzheimer’s Treatment
Could a Novel Light Therapy Help People With Alzheimer’s? – Mount Sinai
Mechanism of Alzheimer’s disease treatment by sound and light stimulation – PMC
Ultrasound Neuromodulation With Transcranial Pulse Stimulation in Alzheimer Disease – JAMA Network
The emerging field of non-invasive brain stimulation in Alzheimer’s disease – Brain, Oxford Academic
Neurostimulation shows promise as potential Alzheimer’s treatment – Medical Xpress
Neurostimulation Device for Alzheimers Granted FDA Breakthrough Status
Cognito Therapeutics Presents Clinical Trial Data at AAIC 2025
Cognito’s Gamma Sensory Stimulation Results – NeurologyLive
